Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma

Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma

2024.03.14
In January 2024, a study led by Professor Gang An from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——American Journal of Hematology(IF=12.8). The title of the study is "Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma". This study represents a significant leap forward in precision medicine for multiple myeloma (MM).
MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities

MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities

2024.03.14
In January 2024, a groundbreaking study spearheaded by Professor Gang An  from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, made its debut in the esteemed journal Haematologica (IF=11.047). The research, titled "MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities" marks a significant advancement in the understanding of multiple myeloma (MM). This comprehensive investigation meticulously analyzes the prognostic impact of MAF translocations, t(14;16) and t(14;20), within the context of MM, shedding light on their independent prognostic significance despite the presence of other chromosomal anomalies. This study not only enhances the scientific community's comprehension of MM's genetic complexity but also paves the way for refining risk stratification and tailoring treatment approaches for affected patients, thereby contributing to the ongoing efforts to improve outcomes in this challenging hematological malignancy.
Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

2024.03.08
In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Signal Transduction And Targeted Therapy (IF=38.104). The title of the study is "Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma". This study sheds light on the promising potential of FCRL5-directed CAR-T cell therapy in the treatment of multiple myeloma (MM).
ASH in 5 Minutes | Prof. An Gang: Immunotherapy Dominates MM Research, Exploration of Drug Resistance Mechanisms Vital

ASH in 5 Minutes | Prof. An Gang: Immunotherapy Dominates MM Research, Exploration of Drug Resistance Mechanisms Vital

2024.01.05
Currently, the highly anticipated 65th American Society of Hematology (ASH) Annual Meeting is underway in San Diego, USA. In the face of the annual pinnacle event in the field of hematologic malignancies, the front-line reporting team of "Hematology Frontier" delves deep, capturing the international cutting-edge developments and witnessing the outstanding performance of "China's good voice" on the global stage. In the realm of Multiple Myeloma (MM), advancements in targeted therapy and cell immunotherapy continue to dominate, making it imperative to comprehensively grasp the therapeutic progress at this year's ASH conference. "Hematology Frontier" had the privilege of interviewing Professor An Gang from the Hematology Hospital of the Chinese Academy of Medical Sciences, who brilliantly dissected the progress in MM.
ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma

ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma

2024.01.05
In the just-concluded 65th American Society of Hematology (ASH) Annual Meeting, CAR-T therapy emerged as a crucial advancement in the treatment of Multiple Myeloma (MM). The only approved BCMA CAR-T in China, Idecabtagene Vicleucel (CT103A), shone brightly. Professor Chunrui Li and her team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, presented a study (abstract 761) reporting the efficacy and safety data of CT103A in refractory/relapsed MM, garnering widespread attention. "Tumor Insights" had the privilege of interviewing Professor Li at the event, delving deep into the advancements in MM treatment and future directions
BCMA/CD19 Dual-Target FasTCAR-T Cells Efficient and Safe in First-Line Treatment of High-Risk Newly Diagnosed Multiple Myeloma Patients

BCMA/CD19 Dual-Target FasTCAR-T Cells Efficient and Safe in First-Line Treatment of High-Risk Newly Diagnosed Multiple Myeloma Patients

2024.01.04
At the 65th American Society of Hematology Annual Meeting in 2023 (ASH), Professor Du Juan and her team from Shanghai Changzheng Hospital presented preliminary findings from a Phase I study (abstract 1022) assessing the efficacy and safety of BCMA/CD19 dual-target FasTCAR-T cells (GC012F) in treating high-risk, newly diagnosed multiple myeloma (HR-NDMM) patients. The study was selected for oral presentation at the conference. In this article, "Tumor Insight" has compiled the abstract content and invited Professor Du Juan to provide commentary for readers' reference.